Lupus Research Alliance News
Lupus Research Alliance Response to Positive Data from Phase 3 Anifrolumab Trial Presented at 2019 ACR/ARP Annual Meeting

NEW YORK, NY – November 11. The Lupus Research Alliance (LRA) congratulates AstraZeneca on new positive results from the Phase 3 TULIP-2 trial (Treatment of Uncontrolled Lupus via the Interferon Pathway) presented at the 2019 ACR/ARP Annual Meeting.  The data showed that the investigational biologic treatment anifrolumab significantly reduced disease activity for people with lupus. […] READ MORE

LRA Applauds Exciting Lupus Research Being Presented at 2019 ACR/ARP Annual Meeting

Includes 16 presentations of studies funded by the Lupus Research Alliance on a variety of immune pathways Results from two clinical studies conducted by LRA-affiliate Lupus Therapeutics (LT) in collaboration with Rilite Foundation and Pfizer to be presented Extensive positive studies focused on lupus, including successful Phase 3 and Phase 2 clinical and mechanistic data […] READ MORE

New Studies Suggest AVISE Lupus Test Improves Diagnosis of Disease

October 28, 2019 Because lupus is hard to diagnose, many patients don’t get the treatments they need, while others get the wrong therapies. Two new studies indicate that the AVISE Lupus blood test can help doctors find out whether patients have lupus. The test builds on seminal studies by Lupus Research Alliance-funded scientist Dr. Joseph […] READ MORE

Lupus Research Alliance Announces 2019 Distinguished Innovator Awards Aimed at New Lupus Treatments

NEW YORK, October 24 — The Lupus Research Alliance proudly announces two exceptional recipients of the 2019 Dr. William E. Paul Distinguished Innovator Award in Lupus and Autoimmunity:  Fabienne Mackay, PhD, and Jeffrey Rathmell, PhD. The highly prestigious up-to-$1 million grant will allow each investigator to test promising approaches for potential new lupus treatments. Dr. Mackay […] READ MORE

Lupus Research Alliance Welcomes New Senior Director of Marketing and Communications

NEW YORK, NY. October 16 — The Lupus Research Alliance (LRA) is pleased to announce that seasoned professional Penny Mitchell has joined the organization as Senior Director of Marketing and Communications. In her new role, Ms. Mitchell will oversee the organization’s strategic communications approach to leading lupus research worldwide and the value of participation by […] READ MORE

Peer-to-Peer Involvement Advances Scientific Exploration

Many dynamics of lupus contribute to the fact that its complexities have eluded the scientific community—but new hope may come from patients themselves. This is why Lupus Therapeutics piloted the Patient Advocates for Lupus Studies (PALS) program in the Summer of 2019. PALS focuses on reaching diverse populations to improve their knowledge and awareness of […] READ MORE

Epilepsy in People with Lupus

October 17, 2019 A new study published in the European Journal of Neurology showed that epilepsy is significantly more common among people with systemic erythematosus lupus (SLE) than the general population. According to the Epilepsy Foundation, epilepsy is a neurological disorder characterized by unpredictable seizures. A seizure is a sudden surge of electrical activity in […] READ MORE

High Levels of Interferon-Alpha Identifies Lupus Patients At Risk for Relapse

October 7, 2019 A new study published in Annals of the Rheumatic Diseases found that among people with lupus, high levels of the protein interferon-alpha, a substance in the immune system that fights viruses, predicts risk of relapse among people in remission. The study looked at 254 people with lupus who were in remission according […] READ MORE

Why Don’t Half of People with Lupus Take Hydroxychlorine As Prescribed?

October 3, 2019 Hydroxychlorine is one of the most common treatments for lupus.  But a new study published in The Journal of Rheumatology looked at why about half of people with lupus do not take hydroxychlorine as prescribed by their healthcare provider. The study looked at 1956 lupus patients 18 years or older being treated […] READ MORE

LRA Pleased to Share News of Lupus Nephritis Clinical Trial Launch

October 1, 2019 The Lupus Research Alliance is pleased to share news about the launch of EQUALISE, a Phase 1b trial that will evaluate the safety and tolerability of an experimental compound itolizumab at various doses in a small group of patients with systemic lupus erythematosus (SLE) and lupus nephritis. Sponsored by the biotechnology company […] READ MORE

Learn and connect with our community!